Harrington Investments INC lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 23,263 shares of the biopharmaceutical company’s stock after selling 790 shares during the period. Harrington Investments INC’s holdings in Gilead Sciences were worth $1,455,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also made changes to their positions in the business. Gradient Investments LLC grew its holdings in Gilead Sciences by 16.1% during the 4th quarter. Gradient Investments LLC now owns 1,076 shares of the biopharmaceutical company’s stock valued at $67,000 after purchasing an additional 149 shares in the last quarter. Waldron Private Wealth LLC grew its holdings in Gilead Sciences by 3.8% during the 3rd quarter. Waldron Private Wealth LLC now owns 4,372 shares of the biopharmaceutical company’s stock valued at $337,000 after purchasing an additional 162 shares in the last quarter. Cornerstone Advisors Inc. grew its holdings in Gilead Sciences by 6.1% during the 3rd quarter. Cornerstone Advisors Inc. now owns 3,120 shares of the biopharmaceutical company’s stock valued at $241,000 after purchasing an additional 178 shares in the last quarter. Boenning & Scattergood Inc. boosted its stake in Gilead Sciences by 0.9% during the 4th quarter. Boenning & Scattergood Inc. now owns 20,176 shares of the biopharmaceutical company’s stock valued at $1,262,000 after acquiring an additional 180 shares during the last quarter. Finally, NewSquare Capital LLC boosted its stake in Gilead Sciences by 0.9% during the 4th quarter. NewSquare Capital LLC now owns 20,165 shares of the biopharmaceutical company’s stock valued at $1,261,000 after acquiring an additional 187 shares during the last quarter. 80.03% of the stock is currently owned by institutional investors.
Shares of NASDAQ:GILD opened at $67.62 on Tuesday. The stock has a market cap of $87.28 billion, a price-to-earnings ratio of 11.00, a PEG ratio of 66.65 and a beta of 1.19. Gilead Sciences, Inc. has a 1-year low of $60.32 and a 1-year high of $82.71. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.36 and a quick ratio of 3.29.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Monday, February 4th. The biopharmaceutical company reported $1.44 EPS for the quarter, missing analysts’ consensus estimates of $1.70 by ($0.26). Gilead Sciences had a net margin of 24.65% and a return on equity of 37.03%. The company had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.52 billion. During the same period last year, the company earned $1.78 earnings per share. The business’s revenue was down 2.6% compared to the same quarter last year. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post 6.23 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 28th. Stockholders of record on Friday, March 15th will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 3.73%. The ex-dividend date of this dividend is Thursday, March 14th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.57. Gilead Sciences’s dividend payout ratio is presently 37.07%.
In other news, Director John C. Martin sold 50,000 shares of the stock in a transaction that occurred on Monday, December 3rd. The stock was sold at an average price of $71.20, for a total value of $3,560,000.00. Following the completion of the sale, the director now owns 2,877,762 shares of the company’s stock, valued at approximately $204,896,654.40. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 1.16% of the company’s stock.
GILD has been the topic of a number of research analyst reports. Oppenheimer upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $85.00 price objective on the stock in a research note on Thursday, January 3rd. Citigroup restated a “buy” rating and issued a $100.00 price target on shares of Gilead Sciences in a research report on Tuesday, February 5th. Zacks Investment Research downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Monday, December 31st. CIBC upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $85.00 price objective on the stock in a research report on Thursday, January 3rd. Finally, Wells Fargo & Co cut their price objective on shares of Gilead Sciences from $95.00 to $89.00 and set an “outperform” rating on the stock in a research report on Tuesday, February 5th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $86.85.
Gilead Sciences Profile
Gilead Sciences, Inc discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Featured Article: How to calculate the intrinsic value of a stock
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.